IsoPlexis (ISO) and Its Competitors Head-To-Head Review

IsoPlexis (NASDAQ:ISOGet Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it contrast to its rivals? We will compare IsoPlexis to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for IsoPlexis and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IsoPlexis 0 2 0 0 2.00
IsoPlexis Competitors 193 1090 1691 59 2.53

IsoPlexis currently has a consensus target price of $1.60, indicating a potential upside of 115.92%. As a group, “Analytical instruments” companies have a potential upside of 14.91%. Given IsoPlexis’ higher probable upside, analysts clearly believe IsoPlexis is more favorable than its rivals.

Institutional and Insider Ownership

44.9% of IsoPlexis shares are owned by institutional investors. Comparatively, 54.5% of shares of all “Analytical instruments” companies are owned by institutional investors. 6.4% of IsoPlexis shares are owned by insiders. Comparatively, 16.3% of shares of all “Analytical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares IsoPlexis and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IsoPlexis -632.41% -127.86% -71.41%
IsoPlexis Competitors -336.82% 230.37% -19.53%

Valuation & Earnings

This table compares IsoPlexis and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
IsoPlexis $16.76 million -$106.00 million -0.27
IsoPlexis Competitors $1.10 billion -$255.49 million 2.31

IsoPlexis’ rivals have higher revenue, but lower earnings than IsoPlexis. IsoPlexis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

IsoPlexis has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, IsoPlexis’ rivals have a beta of 1.04, meaning that their average stock price is 3% more volatile than the S&P 500.

Summary

IsoPlexis rivals beat IsoPlexis on 10 of the 13 factors compared.

IsoPlexis Company Profile

(Get Rating)

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.

Receive News & Ratings for IsoPlexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoPlexis and related companies with MarketBeat.com's FREE daily email newsletter.